55 related articles for article (PubMed ID: 20871029)
1. Apoptosis as a possible candidate mechanism for removal of tamoxifen-related endometrial cells with KRAS mutations.
Tsujioka H; Hachisuga T; Hikita S; Ueda T; Yotsumoto F; Shirota K; Yoshizato T; Kawarabayashi T; Kuroki M; Miyamoto S
Anticancer Res; 2010 Aug; 30(8):3119-23. PubMed ID: 20871029
[TBL] [Abstract][Full Text] [Related]
2. K-ras mutation in tamoxifen-related endometrial polyps.
Hachisuga T; Miyakawa T; Tsujioka H; Horiuchi S; Emoto M; Kawarabayashi T
Cancer; 2003 Nov; 98(9):1890-7. PubMed ID: 14584071
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of endometrial K-ras mutation in tamoxifen-treated patients with breast cancer.
Tsujioka H; Hachisuga T; Fukuoka M; Ueda T; Miyahara D; Horiuchi S; Shirota K; Yoshizato T; Emoto M; Miyamoto S; Kawarabayashi T
Int J Gynecol Cancer; 2009 Aug; 19(6):1052-6. PubMed ID: 19820367
[TBL] [Abstract][Full Text] [Related]
4. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
5. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
Cheng WF; Lin HH; Torng PL; Huang SC
Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen modulates apoptotic pathways in primary endometrial cell cultures.
Stackievicz R; Drucker L; Radnay J; Beyth Y; Yarkoni S; Cohen I
Clin Cancer Res; 2001 Feb; 7(2):415-20. PubMed ID: 11234898
[TBL] [Abstract][Full Text] [Related]
7. Mutagenic potential of alpha-(N2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen.
Terashima I; Suzuki N; Shibutani S
Cancer Res; 1999 May; 59(9):2091-5. PubMed ID: 10232593
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer.
Dibi RP; Zettler CG; Pessini SA; Ayub AV; de Almeida SB; da Silveira GP
Menopause; 2009; 16(2):293-300. PubMed ID: 19034048
[TBL] [Abstract][Full Text] [Related]
9. Alterations of the K-ras and p53 genes in Tamoxifen-associated endometrial carcinoma.
Fujiwara K; Enomoto T; Fujita M; Kanda T; Fujii S; Ito K; Wakasa K; Ishiko O; Ueda M; Yamaguchi S; Kimura T; Umesaki N
Oncol Rep; 2008 May; 19(5):1293-8. PubMed ID: 18425390
[TBL] [Abstract][Full Text] [Related]
10. Estrogen and progesterone receptors in the endometrium of postmenopausal breast cancer patients treated with tamoxifen and progestogens.
Cohen I; Altaras MM; Beyth Y; Shapira J; Figer A; Tepper R; Cordoba M; Yigal D; Bernheim J
Gynecol Oncol; 1997 Apr; 65(1):83-8. PubMed ID: 9103396
[TBL] [Abstract][Full Text] [Related]
11. [The effect of tamoxifen of endometrium].
Bai P; Sun J; Zhang K
Zhonghua Fu Chan Ke Za Zhi; 2001 Apr; 36(4):226-8. PubMed ID: 11783367
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen enhances apoptotic effect of cisplatin on primary endometrial cell cultures.
Drucker L; Stackievicz R; Radnay J; Shapira H; Cohen I; Yarkoni S
Anticancer Res; 2003; 23(2B):1549-54. PubMed ID: 12820422
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen treatment for breast cancer enforces a distinct gene-expression profile on the human endometrium: an exploratory study.
Gielen SC; Kühne LC; Ewing PC; Blok LJ; Burger CW
Endocr Relat Cancer; 2005 Dec; 12(4):1037-49. PubMed ID: 16322341
[TBL] [Abstract][Full Text] [Related]
14. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women.
Marttunen MB; Cacciatore B; Hietanen P; Pyrhönen S; Tiitinen A; Wahlström T; Ylikorkala O
Br J Cancer; 2001 Apr; 84(7):897-902. PubMed ID: 11286468
[TBL] [Abstract][Full Text] [Related]
15. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
16. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer.
Deligdisch L; Kalir T; Cohen CJ; de Latour M; Le Bouedec G; Penault-Llorca F
Gynecol Oncol; 2000 Aug; 78(2):181-6. PubMed ID: 10926800
[TBL] [Abstract][Full Text] [Related]
17. Steroid receptor expression in endometria from women treated with tamoxifen.
Kommoss F; Karck U; Prömpeler H; Pfisterer J; Kirkpatrick CJ
Gynecol Oncol; 1998 Aug; 70(2):188-91. PubMed ID: 9740688
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients].
Otsuka I; Takahashi S; O'uchi K; Akimoto N; Hanari K; Ogaki Y; Enatsu YH; Takigawa A; Takaya H; Tanaka A; Kaseki H; Yamada T
Gan To Kagaku Ryoho; 2010 Feb; 37(2):279-83. PubMed ID: 20154485
[TBL] [Abstract][Full Text] [Related]
19. K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene.
Hachisuga T; Tsujioka H; Horiuchi S; Udou T; Emoto M; Kawarabayashi T
Br J Cancer; 2005 Mar; 92(6):1098-103. PubMed ID: 15756272
[TBL] [Abstract][Full Text] [Related]
20. Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells.
Mandlekar S; Yu R; Tan TH; Kong AN
Cancer Res; 2000 Nov; 60(21):5995-6000. PubMed ID: 11085519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
